APOC3, coronary disease, and complexities of mendelian randomization

Research output: Contribution to journalShort surveypeer-review

34 Scopus citations


Two new studies report that triglyceride (TG)-lowering mutations in APOC3 reduce coronary heart disease (CHD) (Crosby et al., 2014; Jørgensen et al., 2014). Here, we explore limitations of using Mendelian randomization to evaluate CHD risk, including potential confounding by the widespread use of statin therapy.

Original languageEnglish (US)
Pages (from-to)387-389
Number of pages3
JournalCell Metabolism
Issue number3
StatePublished - Sep 2 2014

ASJC Scopus subject areas

  • Physiology
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'APOC3, coronary disease, and complexities of mendelian randomization'. Together they form a unique fingerprint.

Cite this